Drug
Zilucoplan
Zilucoplan: highest development phase Phase 3, developed by Dechra Pharmaceuticals, UCB. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Dechra Pharmaceuticals, UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| zilucoplan (RA101495) NCT04225871 | Phase 3 | Generalized Myasthenia Gravis |
| Zilucoplan NCT06055959 | Phase 2/3 | Generalized Myasthenia Gravis |
| zilucoplan (RA101495) NCT03315130 | Phase 2 | Generalized Myasthenia Gravis |
Latest
No recent events.
Follow Zilucoplan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.